β-Ecdysterone protects SH-SY5Y cells against β-amyloid-induced apoptosis via c-Jun N-terminal kinase- and Akt-associated complementary pathways

• Published in: Laboratory investigation Vol. 98; no. 4; pp. 489 - 499
• Main Authors: Xu, Tianjiao, Niu, Chengu, Zhang, Xiaojie, Dong, Miaoxian
• Format: Journal Article
• Language: English
• Published: New York Elsevier Inc 01.04.2018; Nature Publishing Group US; Nature Publishing Group
• Subjects: 631/154/436; 692/617/375/365/1283; 96; 96/2; Achyranthes; Activation; AKT protein; Alzheimer Disease - drug therapy; Alzheimer Disease - metabolism; Alzheimer's disease; Apoptosis; Apoptosis - drug effects; BAX protein; Bcl-2 protein; c-Jun protein; Caspase; Caspase 9 - metabolism; Caspase-9; Cell Line, Tumor; Cytochrome; Cytochrome c; Cytochromes; Cytochromes c - metabolism; Deactivation; Drug Evaluation, Preclinical; Estrogens; Humans; Hypotheses; Inactivation; JNK protein; Kinases; Laboratory Medicine; MAP kinase; MAP Kinase Kinase Kinase 5 - metabolism; MAP Kinase Signaling System; Medicine; Medicine & Public Health; Menopause; Mitochondria; Neuroprotection; NF-kappa B - metabolism; NF-κB protein; Pathology; Phosphorylation; Phytoestrogens - pharmacology; Phytotherapy; Plant Extracts - pharmacology; Plant Extracts - therapeutic use; Proteins; Proto-Oncogene Proteins c-akt - metabolism; Proto-Oncogene Proteins c-bcl-2 - metabolism; Reactive oxygen species; Scavenging; Toxicity; Transcription factors; β-Amyloid
• ISSN: 0023-6837; 1530-0307
• DOI: 10.1038/s41374-017-0009-0

Recently, the significantly higher incidence of Alzheimer's disease (AD) in women than in men has been attributed to the loss of neuroprotective estrogen after menopause. Does phytoestrogen have the ability to protect against amyloid-β (Aβ) toxicity? The aim of this study was to evaluate hypothesis that β-ecdysterone (β-Ecd) protects SH-SY5Y cells from Aβ-induced apoptosis by separate signaling pathways involving protein kinase B (Akt) and c-Jun N-terminal kinase (JNK). Here, we demonstrate that phytoestrogen β-Ecd inhibits Aβ-triggered mitochondrial apoptotic pathway, as indicated by Bcl-2/Bax ratio elevation, cytochrome c (cyt c) release reduction, and caspase-9 inactivation. Interestingly, β-Ecd upregulates Bcl-2 expression in SH-SY5Y cells under both basal and Aβ-challenged conditions, but downregulates Bax expression only in Aβ-challenged conditions. Subsequently, Akt-dependent NF-κB activation is required for Bcl-2 upregulation, but not Bax downregulation, in response to β-Ecd, which was validated by the use of LY294002 and Bay11-7082. Notably, β-Ecd attenuates the Aβ-evoked reactive oxygen species (ROS) production, apoptosis signal-regulating kinase 1 (ASK1) phosphorylation and JNK activation without altering the basal ASK1 phosphorylation and JNK activation. ROS-scavenging by diphenyleneiodonium (DPI) abrogated the ability of β-Ecd to alter the activation of ASK1. Simultaneously, inhibition of JNK by SP600125 abolished β-Ecd-induced Bax downregulation in Aβ-challenged SH-SY5Y cells, whereas LY294002 failed to do so. Consequently, β-Ecd possesses neuroprotection by different and complementary pathways, which together promote a Bcl-2/Bax ratio. These data support our hypothesis and suggest that β-Ecd is a promising candidate for the treatment of AD.